Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight

Olanzapine LAIPositive

AI Analysis

Summary

Market analysis predicts significant growth in the schizophrenia treatment market through 2036, driven by rising disease prevalence and the anticipated launch of novel long-acting therapies including Olanzapine LAI being developed by Teva Pharmaceutical and MedinCell.

Importance:3/10

Sentiment:

0.50

schizophreniamarket analysispipelinelong-acting therapiesdrug development

Related Companies

$TEVA $MEDCL.PA $RPRX

Read the original article

Published by PR Newswire Biotech on October 7, 2026 2:31 PM

Read Original